EOLS - Evolus to Participate in November Investor Conferences
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will present at the following investment conferences in November.
| Event: |
| Stifel 2023 Healthcare Conference |
| Date: |
| Wednesday, November 15, 2023 |
| Time: |
| 11:30 AM ET |
| Event: |
| 6 th Annual Evercore ISI HealthCONx Conference |
| Date: |
| Tuesday, November 28, 2023 |
| Time: |
| 9:35 AM ET |
Audio webcasts of these events will be available on the investor relations section of Evolus’ website at www.evolus.com . Replays of the webcasts will be available for 90 days after the date of each presentation.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau ® (prabotulinumtoxinA-xvfs), globally licensed under the brand name Nuceiva ® . The product is manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, a line of five unique dermal fillers currently in late-stage development. Visit us at www.evolus.com , and follow us on LinkedIn , X , Instagram or Facebook .
Jeuveau ® and Nuceiva ® are registered trademarks of Evolus, Inc.
Evolysse ™ is a trademark of Evolus, Inc.
Hi-Pure ™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231031666324/en/
Investor Contacts:
Ned Mitchell
Arbor Advisory Group
Email: ir@evolus.com
Media Contact :
Email: media@evolus.com